ERBB2 and colorectal carcinoma: Based on the diagnostic criteria of the HERACLES trial, a phase II study investigating the dual HER2 blockade in patients with HER2-amplified metastatic CRC (20), one of the 28 patients in the relapse or metastasis group had HER2-positive CRC and HER2 amplification was also detected in the cfDNA of the same patient.